patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

  • Aim to develop and manufacture the best technology graphite in the world
  • Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Message: PSTI receives orphan drug status for treatment of Buergers disease 8/25 pr link

Dsc_0077
Rank: [?]
President
Points: [?]
9678
Rating: [?]
Votes: 120 Score: 3.6
  • Currently 3.6/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

I must admit I got a littttttle concerned when they did the big

posted on Sep 01, 11 09:44AM

billion share thing, but they came back with an appropriate split and took care of it. I am now confident management knows what they are doing and that the tech will succeed. Really excited about the good this company can do for people who are seriously huring. My aunt had both legs amputated just below the knee in the four years before she died. Very serious impact on her mental state that Pluristem could have prevented. God bless...

Kirk

New Message

Please login to post a reply

AGORACOM Quick Tips

What Is Twitter? Watch Our 5-Minute Tutorial ... Watch Now

President's D.D.

4-17-12, Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial for the treatment of peripheral artery disease (PAD). read more

Stock Quote

Hub Leaders